## Anna Nowak

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10687796/publications.pdf

Version: 2024-02-01

279701 454834 7,141 33 23 30 citations h-index g-index papers 34 34 34 7539 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The IASLC Lung Cancer Staging Project: Proposals forÂRevision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 39-51.	0.5	3,162
2	The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1204-1223.	0.5	530
3	Mesothelin-family proteins and diagnosis of mesothelioma. Lancet, The, 2003, 362, 1612-1616.	6.3	516
4	The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage GroupingsÂin the Eighth Edition of the TNM Classification of LungÂCancer. Journal of Thoracic Oncology, 2017, 12, 1109-1121.	0.5	342
5	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 300-311.	0.5	338
6	The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 651-665.	0.5	211
7	The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1433-1446.	0.5	201
8	Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis, 2015, 36, 177-185.	1.3	184
9	The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 639-650.	0.5	182
10	The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2112-2119.	0.5	172
11	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal of Thoracic Oncology, 2016, 11, 666-680.	0.5	170
12	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Journal of Thoracic Disease, 2013, 5, E254-307.	0.6	170
13	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2089-2099.	0.5	139
14	The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 2100-2111.	0.5	120
15	Targeting Aggressive Cancer Stem Cells in Glioblastoma. Frontiers in Oncology, 2015, 5, 159.	1.3	107
16	The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 681-692.	0.5	101
17	Soluble mesothelin-related protein—A blood test for mesothelioma. Lung Cancer, 2005, 49, S109-S111.	0.9	99
18	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 344-359.	0.5	87

#	Article	IF	Citations
19	Diagnosing cancer in the bush: a mixed-methods study of symptom appraisal and help-seeking behaviour in people with cancer from rural Western Australia. Family Practice, 2013, 30, 294-301.	0.8	73
20	The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. Journal of Thoracic Oncology, 2016, 11, 2082-2088.	0.5	61
21	An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs, 2012, 30, 387-394.	1.2	59
22	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	0.5	49
23	Diagnosing cancer in the bush: a mixed methods study of GP and specialist diagnostic intervals in rural Western Australia. Family Practice, 2013, 30, 541-550.	0.8	32
24	First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes, 2015, 8, 192.	0.6	15
25	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. Journal of Thoracic Oncology, 2019, 14, 1704-1717.	0.5	8
26	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. Neuro-Oncology, 2019, 21, vi14-vi14.	0.6	5
27	Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol. BMJ Open Respiratory Research, 2020, 7, e000551.	1.2	4
28	COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy Journal of Clinical Oncology, 2014, 32, TPS7611-TPS7611.	0.8	2
29	CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii47-ii47.	0.6	1
30	PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON. Neuro-Oncology, 2020, 22, ii166-ii166.	0.6	1
31	An evaluation of the QUAL-EC in the clinical care of patients with advanced cancer Journal of Clinical Oncology, 2017, 35, 85-85.	0.8	O
32	QOLP-23. PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA REQUIRING TREATMENT WITH DEXAMETHASONE. Neuro-Oncology, 2020, 22, ii179-ii180.	0.6	0
33	CTNI-14. A 3-ARM, PHASE IIA TRIAL OF SAFETY & DEFFICACY OF OLINVACIMAB, A MONOCLONAL ANTIBODY TO VEGFR2 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME WITH IMAGING AND PK/PD ASSESSMENTS: FINAL REPORT. Neuro-Oncology, 2020, 22, ii44-ii45.	0.6	O